#1 Clinical Trials Search in Europe

Obicetrapib

Obicetrapib is an investigational drug currently being studied in clinical trials for its potential to lower cholesterol levels and reduce the risk of cardiovascular disease. This article summarizes key information about ongoing clinical trials evaluating obicetrapib’s efficacy, safety, and effects on lipid profiles in various patient populations.

Table of Contents

What is Obicetrapib?

Obicetrapib is a new medication being developed to help manage cholesterol levels in the body. It belongs to a class of drugs known as CETP inhibitors[1]. CETP stands for Cholesteryl Ester Transfer Protein, which is a protein in your body that affects how cholesterol is processed. By inhibiting or blocking this protein, obicetrapib aims to improve cholesterol levels and potentially reduce the risk of heart problems.

How Does Obicetrapib Work?

Obicetrapib works by targeting a specific process in the body that affects cholesterol levels. It inhibits the CETP protein, which normally transfers cholesterol between different types of lipoproteins (particles that carry cholesterol in the blood). By blocking this transfer, obicetrapib can help:

  • Decrease levels of “bad” cholesterol (LDL-C, or low-density lipoprotein cholesterol)
  • Increase levels of “good” cholesterol (HDL-C, or high-density lipoprotein cholesterol)
  • Reduce other harmful lipids like apolipoprotein B (ApoB) and non-HDL cholesterol

This unique mechanism of action makes obicetrapib a promising option for patients who may not respond well to or cannot tolerate other cholesterol-lowering medications[2].

What Conditions Does Obicetrapib Treat?

Obicetrapib is being studied for several conditions related to cholesterol and heart health:

  • High Cholesterol (Hypercholesterolemia): This is the primary condition that obicetrapib targets. It’s being tested in patients with persistently high cholesterol levels despite using other treatments[3].
  • Familial Hypercholesterolemia (FH): This is a genetic condition that causes very high cholesterol levels from birth. Obicetrapib is being studied in patients with a form of FH called Heterozygous Familial Hypercholesterolemia (HeFH)[3].
  • Atherosclerotic Cardiovascular Disease (ASCVD): This refers to the buildup of plaque in arteries, which can lead to heart attacks and strokes. Obicetrapib is being tested to see if it can reduce the risk of cardiovascular events in patients with ASCVD[4].
  • Early Alzheimer’s Disease: Interestingly, obicetrapib is also being studied for its potential effects on early Alzheimer’s disease, particularly in patients with specific genetic risk factors (APOE4 carriers)[5].

Obicetrapib in Clinical Trials

Obicetrapib is currently undergoing extensive clinical trials to evaluate its safety and effectiveness. These trials are at various stages:

  • Phase 1 studies: These early studies are looking at how obicetrapib affects lipoprotein metabolism and how it behaves in patients with moderate liver impairment[6][7].
  • Phase 2 studies: These trials are examining the drug’s effects in more detail, including its impact on cholesterol levels and its potential in early Alzheimer’s disease[1][5].
  • Phase 3 studies: These larger, more comprehensive trials are evaluating obicetrapib’s long-term effectiveness and safety in patients with high cholesterol, familial hypercholesterolemia, and cardiovascular disease[3][4].

How Effective is Obicetrapib?

While final results from many trials are still pending, early data suggests that obicetrapib may be quite effective in managing cholesterol levels. Studies are measuring its impact on several key markers:

  • LDL-C reduction: This is the primary measure of effectiveness for most trials. Obicetrapib has shown promising results in lowering LDL-C levels[1].
  • Apolipoprotein B (ApoB) reduction: ApoB is another important marker of cardiovascular risk. Obicetrapib appears to effectively lower ApoB levels[8].
  • HDL-C increase: Unlike some other cholesterol medications, obicetrapib may also increase levels of “good” cholesterol[1].
  • Lipoprotein(a) reduction: Some studies are looking at obicetrapib’s effect on lipoprotein(a), another risk factor for heart disease[9].

How is Obicetrapib Administered?

Obicetrapib is being developed as an oral medication, which means it’s taken by mouth. In most clinical trials, it’s being tested as a once-daily tablet. The doses being studied most frequently are:

  • 5 mg daily
  • 10 mg daily

Some studies are also looking at lower doses, such as 2.5 mg daily[10]. The optimal dose may vary depending on the specific condition being treated and individual patient factors.

Obicetrapib in Combination Therapy

Many studies are exploring how obicetrapib works when combined with other cholesterol-lowering medications:

  • With statins: Obicetrapib is often studied as an “add-on” therapy for patients already taking high-intensity statin medications[1].
  • With ezetimibe: Some trials are looking at combining obicetrapib with ezetimibe, another type of cholesterol-lowering drug[8].
  • With evolocumab (Repatha): A study is examining how obicetrapib works when combined with evolocumab, a different class of cholesterol medication[9].

These combination approaches may offer more powerful cholesterol-lowering effects for patients who need additional treatment beyond standard therapies.

Ongoing Research and Future Prospects

Research on obicetrapib is ongoing, with several exciting areas of investigation:

  • Cardiovascular outcomes: A large study called PREVAIL is looking at whether obicetrapib can reduce the risk of major cardiovascular events like heart attacks and strokes in patients with atherosclerotic cardiovascular disease[4].
  • Alzheimer’s disease: Researchers are exploring whether obicetrapib might have beneficial effects on the brain, potentially impacting the progression of early Alzheimer’s disease[5].
  • Genetic factors: Some studies are focusing on how obicetrapib works in patients with specific genetic variations that affect cholesterol metabolism[3].
  • Long-term safety: As with any new medication, researchers are carefully monitoring the long-term safety profile of obicetrapib to ensure its benefits outweigh any potential risks.

While obicetrapib shows promise, it’s important to remember that it’s still an investigational drug. More research is needed before it can be approved for widespread use. Patients interested in obicetrapib should discuss current treatment options with their healthcare providers and consider participating in clinical trials if appropriate.

Trial Phase Patient Population Dosages Tested Primary Outcomes Key Findings
Phase 1 Healthy adults and those with moderate hepatic impairment 10 mg single dose Pharmacokinetics, safety Data not yet available
Phase 2 Patients on high-intensity statin therapy 5 mg, 10 mg daily Change in LDL-C levels Data not yet available
Phase 2 Japanese patients on stable statin therapy 2.5 mg, 5 mg, 10 mg daily Change in LDL-C levels Data not yet available
Phase 2a Patients with early Alzheimer’s disease 10 mg daily Changes in CSF and plasma lipid parameters Data not yet available
Phase 3 Patients with HeFH and/or ASCVD 10 mg daily Change in LDL-C levels, MACE Ongoing

FAQ

  • What is obicetrapib and how does it work? Obicetrapib is an investigational drug that belongs to a class called CETP inhibitors. It works by blocking an enzyme called cholesteryl ester transfer protein (CETP), which is involved in cholesterol metabolism. By inhibiting CETP, obicetrapib may help lower LDL (bad) cholesterol levels and raise HDL (good) cholesterol levels.
  • What conditions is obicetrapib being studied for? Obicetrapib is primarily being studied for treating high cholesterol (hypercholesterolemia), including in patients with familial hypercholesterolemia. It's also being evaluated for its potential to reduce the risk of cardiovascular events in patients with atherosclerotic cardiovascular disease.
  • What dosages of obicetrapib are being tested? Clinical trials are testing various dosages of obicetrapib, including 2.5 mg, 5 mg, and 10 mg daily doses. The 10 mg dose appears to be the most common in later-stage trials.
  • How is obicetrapib being evaluated in clinical trials? Obicetrapib is being evaluated in placebo-controlled, randomized trials. These studies are measuring its effects on cholesterol levels (particularly LDL-C), other lipid parameters, and cardiovascular outcomes. Some trials are testing obicetrapib alone, while others are studying it in combination with other cholesterol-lowering medications.
  • What are the main outcomes being measured in obicetrapib trials? The main outcomes being measured include changes in LDL cholesterol levels, changes in other lipid parameters (like apolipoprotein B and HDL cholesterol), and in some longer-term studies, the occurrence of major adverse cardiovascular events (MACE) such as heart attacks and strokes.

Ongoing Clinical Trials on Obicetrapib

  • Comparison of Obicetrapib and Bempedoic Acid in Patients with Dyslipidemia at High to Very High Cardiovascular Risk

    Recruiting

    1 1 1
    Investigated drugs:
    Czechia Germany Italy The Netherlands Poland Slovakia +1

  • A study to evaluate the effects of obicetrapib and ezetimibe on cholesterol levels in adults with type 2 diabetes or metabolic syndrome

    Recruiting

    1 1
    Investigated drugs:
    Czechia The Netherlands Slovakia

  • Study on the Effects of Obicetrapib and Ezetimibe on Coronary Plaque in Patients with Atherosclerotic Cardiovascular Disease

    Recruiting

    1 1
    Investigated drugs:
    Czechia Hungary Italy The Netherlands Poland Spain

  • Study on the Effect of Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease Not Adequately Managed by Current Lipid-Lowering Treatments

    Not recruiting

    1 1
    Investigated drugs:
    Bulgaria Croatia Czechia Denmark Finland Germany +7

Glossary

  • LDL-C: Low-Density Lipoprotein Cholesterol, often called 'bad' cholesterol. High levels of LDL-C in the blood can lead to buildup in artery walls, increasing the risk of heart disease.
  • HDL-C: High-Density Lipoprotein Cholesterol, often called 'good' cholesterol. HDL-C helps remove other forms of cholesterol from the bloodstream.
  • Apolipoprotein B (ApoB): A protein that is a major component of many lipoproteins, particularly LDL. ApoB levels are often used as an indicator of cardiovascular risk.
  • CETP inhibitor: A class of drugs that work by inhibiting the cholesteryl ester transfer protein (CETP), which is involved in the transfer of cholesterol between different lipoproteins in the blood.
  • Familial Hypercholesterolemia (FH): An inherited condition characterized by very high levels of LDL cholesterol from birth, leading to an increased risk of early heart disease.
  • Atherosclerotic Cardiovascular Disease (ASCVD): A condition where plaque builds up inside the arteries, which can lead to serious problems, including heart attack, stroke, or even death.
  • Statin: A class of drugs commonly used to lower cholesterol levels by blocking a substance your body needs to make cholesterol.
  • Ezetimibe: A medication that lowers cholesterol by reducing its absorption in the intestines.
  • Placebo: An inactive substance or treatment used in clinical trials as a control to compare with the active drug being tested.
  • Randomized controlled trial: A type of scientific experiment where participants are randomly allocated to receive either the treatment under investigation or a placebo/standard treatment, allowing for comparison between groups.
  • Major Adverse Cardiovascular Events (MACE): A composite endpoint used in cardiovascular research that typically includes events such as cardiovascular death, heart attack, and stroke.

References

  1. https://clinicaltrials.gov/study/NCT04753606
  2. https://clinicaltrials.gov/study/NCT05142722
  3. https://clinicaltrials.gov/study/NCT05425745
  4. https://clinicaltrials.gov/study/NCT05202509
  5. https://clinicaltrials.gov/study/NCT05161715
  6. https://clinicaltrials.gov/study/NCT05972278
  7. https://clinicaltrials.gov/study/NCT06048302
  8. https://clinicaltrials.gov/study/NCT05266586
  9. https://clinicaltrials.gov/study/NCT06496243
  10. https://clinicaltrials.gov/study/NCT05421078